Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity - Annals of Oncology
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
Cyclophosphamide - Wikipedia
Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication - ScienceDirect
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM) -
Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer
Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial | SpringerLink
Metronomic cyclophosphamide‑induced long‑term remission after recurrent high‑grade serous ovarian cancer: A case study
A) Antitumor activity of metronomic cyclophosphamide, single low-dose... | Download Scientific Diagram
Metronomic Cyclophosphamide with Cisplatin and Bevacizumab: A New Chemotherapeutic Regimen for Refractory Anaplastic Ependymoma | Anticancer Research
Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?: Trends in Cancer
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study | BMC Cancer | Full Text
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2 | Molecular Cancer | Full Text
Impact of metronomic cyclophosphamide (mCy) on regulatory T cells over... | Download Scientific Diagram
Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators | BMC Cancer | Full Text
Effects of sunitinib, lenalidomide, metronomic cyclophosphamide alone,... | Download Scientific Diagram
